(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 18.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Genmab A's revenue in 2024 is $2,555,827,338.On average, 6 Wall Street analysts forecast GMAB's revenue for 2024 to be $187,549,257,524, with the lowest GMAB revenue forecast at $180,324,596,354, and the highest GMAB revenue forecast at $193,543,899,317. On average, 5 Wall Street analysts forecast GMAB's revenue for 2025 to be $228,469,255,426, with the lowest GMAB revenue forecast at $218,558,216,598, and the highest GMAB revenue forecast at $236,289,750,624.
In 2026, GMAB is forecast to generate $289,414,460,730 in revenue, with the lowest revenue forecast at $262,828,863,455 and the highest revenue forecast at $328,742,217,660.